氯胺酮在抗抑郁治疗领域里的最新研究进展
The Latest Research Progress of Ketamine in the Field of Antidepressant Treatment
DOI: 10.12677/ACM.2023.13112403, PDF,   
作者: 周小东, 王 朋, 贾慧贤, 胡兴娟, 张俊纳, 刘知霞:中国人民解放军联勤保障部队第980医院(白求恩国际和平医院)精神心理科,中国融通集团医疗健康管理公司正定二五六医院精神卫生中心,河北 正定;刘知源*:中国人民解放军联勤保障部队第983医院心理科,天津
关键词: 氯胺酮艾司氯胺酮难治性抑郁症疗效Ketamine Esketamine Treatment-Resistant Depression Effect
摘要: 目的:欲了解有关氯胺酮对抑郁症状的疗效和作用机制探讨的进展。方法:收集近几十年来在几个常用医学搜素网站上发表的有关氯胺酮及其衍生物,针对难治性抑郁症产生快速起效和相关作用机制探讨的文章。结果:共收集来源于PubMed、Medline等医学文献数据库的相关文章18篇,其中综述类文章4篇,作为重点汇总分析。结论:氯胺酮及其衍生物艾司氯胺酮具有快速起效的抗抑郁效果。成人有效剂量在0.5毫克~1.0毫克/公斤体重,单次静脉注射时间不少于40分钟。平均起效时间1.5小时,达峰时间3小时。鼻腔内喷雾给药效果相似。口服该药和儿童慎用。作用机制仍然不甚明了。需要进一步观察长期用药带来的风险。
Abstract: Objective: To probe about the progress in the efficacy and mechanism of Ketamine in the treatment of depression. Methods: We collected articles on search websites in recent decades on the rapid on-set and related mechanisms of Ketamine and Esketamine in the treatment-refractory depression. Results: A total of 18 relevant articles were collected from the PubMed, Medline etc. website medi-cal literature database, including 4 review articles, as a key summary and analysis. Conclusion: Ketamine and Esketamine have a rapid antidepression effect. The effective dose for adults is be-tween 0.5~1.0 milligrams per kilogram of body weight, with a single injection time of no less than 40 minutes. The average onset time is 1.5 hour and the peak time is 3 hours. Intranasal spray has similar efficacy and oral administration is ineffective and should be used with caution in children. The mechanism of action is still unclear. Further observation is needed on the risks associated with long-term medication use.
文章引用:周小东, 王朋, 贾慧贤, 胡兴娟, 张俊纳, 刘知霞, 刘知源. 氯胺酮在抗抑郁治疗领域里的最新研究进展[J]. 临床医学进展, 2023, 13(11): 17146-17155. https://doi.org/10.12677/ACM.2023.13112403

参考文献

[1] Walter, S. (2020) A Systematic Review and Meta-Analysis of the Efficacy of Intravenous Ketamine Infusion for Treat-ment Resistant Depression: January 2009-January 2019. Journal of Affective Disorders, 277, 831-841. [Google Scholar] [CrossRef] [PubMed]
[2] Elia, E., Grace, W., Cavanaugh, B.A., et al. (2019) Comprehensive Assessment of Side Effects Associated with a Single Dose of Ketamine in Treatment-Resistant Depression. Journal of Affective Disorders, 263, 568-575.
[3] Fava, M., Marlene, P., Flynn, M., et al. (2018) Double-Blind, Place-bo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD). Molecular Psychiatry, 25, 1592-1603. [Google Scholar] [CrossRef] [PubMed]
[4] Kryst, J., Kawalec, P., Mikrut, A., et al. (2020) Efficacy of Single and Repeated Administration of Ketamine in Unipolar and Bipolar Depression: A Meta-Analysis of Randomized Clinical Trials. Pharmacological Reports, 72, 543-562.
[5] Zimmermann, K.S., Richardson, R. and Baker, K.D. (2020) Es-ketamine as a Treatment for Paediatric Depression: Questions of Safety and Efficacy. The Lancet Psychiatry, 7, 827-829. [Google Scholar] [CrossRef
[6] Corriger, A. and Pickering, G. (2019) Ketamine and Depres-sion: A Narrative Review. Drug Design, Development and Therapy, 13, 3051-3067. [Google Scholar] [CrossRef
[7] Bartoli, F. and Wlkinson, S.T. (2019) Ketamine and Esketamine for Suicidal Ideation: Recent Progress and Practical Issues. Australian & New Zealand Journal of Psychiatry, 54, 206-207. [Google Scholar] [CrossRef] [PubMed]
[8] Domany, Y., Shelton, R.C. and McCullumsmith, C.B. (2019) Ketamine for Acute Suicidal Ideation, an Emergency Department Intervention: A Randomized, Double-Blind, Place-bo-Controlled, Proof-of-Concept Trial. [Google Scholar] [CrossRef
[9] Witt, K., Potts, J., Hubers, A., et al. (2019) Ketamine for Suicidal Idea-tion in Adults with Psychiatric Disorders: A Systematic Review and Meta-Analysis of Treatment Trials. Australian & New Zealand Journal of Psychiatry, 54, 29-45. [Google Scholar] [CrossRef] [PubMed]
[10] Ren, L., Deng, J., Min, S., et al. (2018) Ketamine in Electrocon-vulsive Therapy for Depressive Disorder: A Systematic Review and Meta-Analysis. Journal of Psychiatric Research, 104, 144-156. [Google Scholar] [CrossRef] [PubMed]
[11] Ritter, P., Findeis, H. and Bauer, M. (2019) Ketamine in the Treatment of Depressive Episodes. Pharmacopsychiatry, 53, 45-50. [Google Scholar] [CrossRef] [PubMed]
[12] Sakurai, H., Jain, F., Foster, S., et al. (2020) Long-Term Outcome in Outpatients with Depression Treated with Acute and Maintenance Intravenous Ketamine: A Retrospective Chart Review. Journal of Affective Disorders, 276, 660-666. [Google Scholar] [CrossRef] [PubMed]
[13] Yang, C., Yang, J.J., Luo, A.L., et al. (2019) Molecular and Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine Enantiomers and Its Metabolites. Translational Psychi-atry, 9, 280-289. [Google Scholar] [CrossRef] [PubMed]
[14] Peng, F.Z., Fan, J., Ge, T.T., et al. (2020) Rapid An-ti-Depressant-Like Effects of Ketamine and Other Candidates: Molecular and Cellular Mechanisms. Cell Proliferation, 53, e12804. [Google Scholar] [CrossRef] [PubMed]
[15] Włodarczyk, A. and Cubała, W.J. (2020) Safety and Tolerability of Ketamine Use in Treatment-Resistant Bipolar Depression Patients with Regard to Central Nervous System Sympto-matology: Literature Review and Analysis. Medicina, 56, Article No. 67. [Google Scholar] [CrossRef] [PubMed]
[16] McIntyrea, R.S., Carvalhoa, I.P., Lui Leanna, M.W., et al. (2020) The Effect of Intravenous, Intranasal, and Oral Ketamine in Mood Disorders: A Meta-Analysis. Journal of Affective Dis-orders, 276, 576-584. [Google Scholar] [CrossRef] [PubMed]
[17] McIntyre, R.S., Lipsits, O., Rodrigues, N.B., et al. (2022) The Ef-fectiveness of Ketamine on Anxiety, Irritability, and Agitation: Implications for Treating Mixed Feature in Adults with Major Depressive or Bipolar Disorder. Bipolar Disorders, 22, 831-840. [Google Scholar] [CrossRef] [PubMed]
[18] Abdallah, C.G., Sanacora, G., Duman, R.S., et al. (2018) The Neurobiology of Depression, Ketamine and Rapid-Acting Antidepressants: Is It Glutamate Inhibition or Activation? Pharmacology and Therapeutics, 190, 148-158. [Google Scholar] [CrossRef] [PubMed]
[19] 丁钦, 解成兰, 岳苏阳, 等. 艾司氯胺酮临床应用研究进展[J]. 实用药物与临床, 2022, 25(8): 754-758.
[20] 姚博炜, 郁丽娜, 刘鹤, 等. 艾司氯胺酮在临床应用中的研究进展[J]. 齐齐哈尔医学院学报, 2022, 43(6): 566-570.
[21] 贾涛, 腾金亮. 新型麻醉镇痛药: 艾司氯胺酮[J]. 中国临床药理学与治疗学, 2022, 27(7): 834-840.